Health Canada approves BeiGene's Brukinsa for marginal zone lymphoma
Health Canada has granted marketing approval to BeiGene’s Brukinsa to treat marginal zone lymphoma (R/R MZL) in adult individuals.
Jane Huang Librepath Wikipedia Beigene Brukinsa Contract Pharmaceutical Development Services Health Canada Drug Discovery Research
Source: pharmaceutical-technology.com